Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy.
Derek W EbnerJohn B KisielPublished in: Current gastroenterology reports (2020)
Stool-based CRC screening detects screen-relevant colorectal neoplasia and outperforms a currently available plasma assay. Though modestly sensitive for CRC, adherence to annual fecal immunochemical testing (FIT) is sub-optimal. Multi-target stool DNA (MT-sDNA) has greater adherence, superior sensitivity for screen-relevant lesions (including those in the proximal colon and sessile serrated architecture), and equivalent specificity to FIT over a 3-year period. Stool-based CRC screening tests are anticipated to reduce the incidence and mortality of CRC through detection of early-stage cancers and high-risk polyps. These endpoints in performance will need to be met by emerging blood sample-based tests in order have meaningful impact in clinical practice.
Keyphrases
- colorectal cancer screening
- early stage
- high throughput
- clinical practice
- risk factors
- high grade
- cardiovascular events
- circulating tumor
- cardiovascular disease
- single molecule
- cell free
- radiation therapy
- sentinel lymph node
- tyrosine kinase
- adipose tissue
- glycemic control
- skeletal muscle
- coronary artery disease
- metabolic syndrome
- lymph node
- chronic rhinosinusitis
- quantum dots
- sensitive detection